NO942850D0 - - Google Patents

Info

Publication number
NO942850D0
NO942850D0 NO942850A NO942850A NO942850D0 NO 942850 D0 NO942850 D0 NO 942850D0 NO 942850 A NO942850 A NO 942850A NO 942850 A NO942850 A NO 942850A NO 942850 D0 NO942850 D0 NO 942850D0
Authority
NO
Norway
Prior art keywords
aicd2
relates
antigen
antibodies
lymphocyte
Prior art date
Application number
NO942850A
Other languages
English (en)
Norwegian (no)
Other versions
NO942850L (no
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO942850D0 publication Critical patent/NO942850D0/no
Publication of NO942850L publication Critical patent/NO942850L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
NO942850A 1993-08-02 1994-08-01 Bispesifikke triggermolekyler som gjenkjenner lymfocyttantigen CD 2 og tumorantigener NO942850L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93112330 1993-08-02

Publications (2)

Publication Number Publication Date
NO942850D0 true NO942850D0 (de) 1994-08-01
NO942850L NO942850L (no) 1995-02-03

Family

ID=8213129

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942850A NO942850L (no) 1993-08-02 1994-08-01 Bispesifikke triggermolekyler som gjenkjenner lymfocyttantigen CD 2 og tumorantigener

Country Status (20)

Country Link
US (1) US5798229A (de)
EP (1) EP0637593B1 (de)
JP (2) JP3822653B2 (de)
KR (1) KR100347465B1 (de)
AT (1) ATE199378T1 (de)
AU (1) AU683659B2 (de)
CA (1) CA2129183C (de)
CZ (1) CZ291071B6 (de)
DE (1) DE69426743T2 (de)
DK (1) DK0637593T3 (de)
ES (1) ES2156587T3 (de)
GR (1) GR3035926T3 (de)
HU (1) HU218100B (de)
NO (1) NO942850L (de)
PL (1) PL176761B1 (de)
PT (1) PT637593E (de)
RU (1) RU2203319C2 (de)
SK (1) SK283133B6 (de)
UA (1) UA40577C2 (de)
ZA (1) ZA945753B (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826695B1 (de) * 1996-09-03 2001-12-12 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US6863887B1 (en) * 1998-03-30 2005-03-08 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
CA2731416A1 (en) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
ES2267275T3 (es) * 1998-07-10 2007-03-01 Connex Gmbh Reactivo inmunologico que interacciona especificamente con el dominio extracelular de la cadena zeta humana.
WO2000018806A1 (de) * 1998-09-25 2000-04-06 Horst Lindhofer Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
CA2442066C (en) 2001-04-02 2005-11-01 Wyeth Pd-1, a receptor for b7-4, and uses therefor
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
RS20050300A (en) 2002-10-16 2007-08-03 Euro-Celtique S.A., Antibodies that bind cell-associated ca 125/0772p and methods of use thereof
WO2004087759A2 (en) * 2003-03-28 2004-10-14 Elusys Therapeutics, Inc. Method and compositions for conversion of antibody activity
AU2004256021A1 (en) * 2003-05-09 2005-01-20 University Of Massachusetts Non-human animals expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor
JP2007510738A (ja) * 2003-11-06 2007-04-26 アイコス、コーポレーション ＣＤ１１ｄ（α−ｄ）インテグリンに特異的に結合する組成物を使用した慢性疼痛を処置する方法
WO2005057223A2 (en) * 2003-12-04 2005-06-23 Applied Research Systems Ars Holding N.V. Methods for identifying modulators of active kit tyrosine kinase receptor
JP2008518947A (ja) * 2004-10-29 2008-06-05 エルシス セラピューティクス， インク． 免疫応答のクリアランス及び誘導におけるｃｒ１結合分子の使用
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
EP3689912A1 (de) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstitution in cdr
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
EP2050764A1 (de) * 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) * 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) * 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP2011518313A (ja) 2008-01-15 2011-06-23 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 急性骨髄性白血病幹細胞のマーカー
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
PT3903829T (pt) 2009-02-13 2023-06-02 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5501439B2 (ja) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
KR101456326B1 (ko) 2009-04-07 2014-11-12 로슈 글리카트 아게 3가, 이중특이적 항체
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
PL2477648T3 (pl) 2009-09-15 2022-11-07 The Board Of Trustees Of The Leland Stanford Junior University Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych
CN104945509A (zh) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
EP2481752B1 (de) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modifizierte konstante antikörperregionen
US8968740B2 (en) 2009-11-13 2015-03-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
EP3511023A1 (de) * 2009-12-02 2019-07-17 Imaginab, Inc. J591-minikörper und cys-diakörper zur adressierung des prostataspezifischen membranantigens (psma) und verfahren zu deren verwendung
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
RU2606264C2 (ru) * 2009-12-25 2017-01-10 Чугаи Сеияку Кабушики Каиша Способ полипептидной модификации для очистки полипептидных мультимеров
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
RU2624027C2 (ru) * 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
MY166429A (en) 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
BR112013013311A2 (pt) 2010-11-30 2017-09-19 Chugai Pharmaceutical Co Ltd agente terapêutico de indução de citotoxicidade
EP2655413B1 (de) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
EP2681240B1 (de) 2011-02-28 2017-08-16 F. Hoffmann-La Roche AG Monovalente antigenbindende proteine
EP2681239B8 (de) 2011-02-28 2015-09-09 F. Hoffmann-La Roche AG Antigenbindende proteine
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
MX359384B (es) 2011-10-11 2018-09-25 Genentech Inc Conjunto mejorado de anticuerpos bisespecificos.
CN104159921B (zh) * 2011-12-15 2018-05-04 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
BR112014019579A2 (pt) 2012-02-10 2019-10-15 Genentech, Inc Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
EP2879710B1 (de) 2012-08-03 2019-11-13 Dana-Farber Cancer Institute, Inc. Medizinische verwendungen von immunzellenaktivierungsmodulierenden substanzen und entsprechende screeningverfahren
EP3586874A1 (de) 2012-08-14 2020-01-01 IBC Pharmaceuticals, Inc. Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten
EP4035689A1 (de) 2012-12-13 2022-08-03 Immunomedics Inc. Dosierungen von immunkonjugaten von antikörpern und sn-38 für verbesserte wirksamkeit und reduzierte toxizität
EP3293275B1 (de) 2013-06-06 2021-08-04 Dana-Farber Cancer Institute, Inc. Zusammensetzung und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
US20160175401A1 (en) 2013-07-31 2016-06-23 Dana-Farber Cancer Institute Inc. Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
KR102441231B1 (ko) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
WO2015052230A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11046763B2 (en) 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
AU2015219495B2 (en) 2014-02-21 2019-11-21 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
DK3126383T3 (en) 2014-04-03 2019-04-01 Igm Biosciences Inc MODIFIED J-CHAIN
EP2930188A1 (de) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunktionelles Antigen-bindendes Molekül
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
EP3148580B1 (de) 2014-05-29 2021-01-20 MacroGenics, Inc. Trispezifische bindungsmoleküle mit spezifischer bindung an mehrere krebsantigene und verfahren zur verwendung davon
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
DK3265575T3 (da) 2015-03-04 2021-05-31 Igm Biosciences Inc Cd20-bindende molekyler og anvendelser deraf
CN108368169A (zh) 2015-03-18 2018-08-03 约翰霍普金斯大学 靶向钾通道kcnk9的新的单克隆抗体抑制剂
EP3279216A4 (de) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von polypeptid-hetero-oligomer
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
SI3316885T1 (sl) 2015-07-01 2021-09-30 Immunomedics, Inc. Imunokonjugati protitelo-SN-38 z linkerjem CL2A
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
DK3356401T3 (da) 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
EP3433365B1 (de) 2016-03-21 2023-08-02 Dana-Farber Cancer Institute, Inc. T-zell-erschöpfungszustandsspezifische genexpressionsregulatoren und verwendungen davon
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
WO2018112033A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs
EP3558360A1 (de) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Behandlung von tumoren mit anti-csf-1r-antikörper in kombination mit einem anti-pd-l1-antikörper nach versagen einer anti-pd-l1/pd1-behandlung
RU2663104C1 (ru) * 2017-07-13 2018-08-01 Общество с ограниченной ответственностью "Реал Таргет" Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей
EP3972993A1 (de) * 2019-05-21 2022-03-30 Novartis AG Variante cd58-domänen und deren verwendungen
EP4342497A1 (de) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antikörper mit reduzierter bindungsaffinität für antigen
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023201226A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2024059183A1 (en) 2022-09-14 2024-03-21 President And Fellows Of Harvard College Methods and compositions for modulation of piezo1 in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260880A3 (de) * 1986-09-11 1990-03-07 Dana-Farber Cancer Institute, Inc. Verfahren zur Auslösung der Zytotoxizität
EP0294703B1 (de) * 1987-06-10 1995-05-10 Dana-Farber Cancer Institute, Inc. Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
CZ282603B6 (cs) * 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky

Also Published As

Publication number Publication date
NO942850L (no) 1995-02-03
JP3822653B2 (ja) 2006-09-20
PT637593E (pt) 2001-08-30
GR3035926T3 (en) 2001-08-31
SK283133B6 (sk) 2003-03-04
CA2129183C (en) 2006-05-16
US5798229A (en) 1998-08-25
CZ291071B6 (cs) 2002-12-11
DE69426743D1 (de) 2001-04-05
UA40577C2 (uk) 2001-08-15
HUT71309A (en) 1995-11-28
KR950005327A (ko) 1995-03-20
PL304510A1 (en) 1995-02-06
ATE199378T1 (de) 2001-03-15
DK0637593T3 (da) 2001-06-25
HU218100B (hu) 2000-06-28
JP2005336207A (ja) 2005-12-08
JP4231862B2 (ja) 2009-03-04
CA2129183A1 (en) 1995-02-03
PL176761B1 (pl) 1999-07-30
CZ180294A3 (en) 1995-02-15
AU683659B2 (en) 1997-11-20
EP0637593A1 (de) 1995-02-08
SK91294A3 (en) 1996-11-06
DE69426743T2 (de) 2001-08-16
JPH0789873A (ja) 1995-04-04
KR100347465B1 (ko) 2003-03-03
ES2156587T3 (es) 2001-07-01
HU9402220D0 (en) 1994-10-28
RU2203319C2 (ru) 2003-04-27
RU94028282A (ru) 1996-07-20
ZA945753B (en) 1995-03-15
AU6869894A (en) 1995-02-09
EP0637593B1 (de) 2001-02-28

Similar Documents

Publication Publication Date Title
NO942850D0 (de)
ATE123652T1 (de) Antigene.
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
EP1681305A3 (de) Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
GR3022969T3 (en) Products for the treatment of endotoxic shock in a mammal
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
AU2190997A (en) Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
EP0741868A1 (de) Immunologische bestimmungen von prostata-spezifischem antigen
GR3031692T3 (en) Recombinant anti-vla4 antibody molecules.
ATE233814T1 (de) Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
IL89124A0 (en) Method for reducing immunoglobulin e responses
DE59308000D1 (de) Immunoassay zum nachweis von kollagen oder kollagenfragmenten
NZ501990A (en) Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE69033457T2 (de) Prohormonspaltungsplatzblockierungsantikörper
ES2062032T3 (es) Antagonista de interleuquina-5 para prevenir o reducir la eosinofilia.
EP0420848A4 (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
AU6162794A (en) Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor